공시 • Apr 25
Purple Biotech Ltd Announces Establishment of Scientific Advisory Board
Purple Biotech Ltd. announced the establishment of a SAB, including world-renowned experts, to advise the Company on the development of candidates from its next-generation CAPTN-3 tri-specific antibody platform. SAB Members: Amir Horowitz, PhD- an expert in natural killer (NK) cell biology and tumor-immune interactions, Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, Icahn School of Medicine at Mount SinaiAfshin Dowlati, MD- Professor, Department of Medicine and Associate Director for Clinical Research, Case Comprehensive Cancer Center at Case Western Reserve University with extensive experience in early-phase clinical development of T-cell engager therapies in solid tumors, including DLL3-targeted approaches. Alexander Shoushtari, MD- Associate Attending Physician, Melanoma Medical Oncologist and Cellular Therapist at Memorial Sloan Kettering Cancer Center and clinical investigator involved in the development of tebentafusp, one of the first approved T-cell engager therapies in solid tumors. Max S. Topp, MD- Head of Hematology and Associate Professor for Translational Immunology at the Universitätsklinikum Würzburg, Germany Medical Clinic who played a key role in the early clinical development of blinatumomab, one of the first approved bispecific T-cell engager therapies. Amir Horowitz, PhD is an Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. His research focuses on harnessing NK and CD8 T cells for antitumor effector functions and has demonstrated a novel immunotherapeutic target axis involving the interaction between HLA-E expressing tumor cells and NKG2A-positive NK and CD8 T cells, which suppresses immune responses in treatment-resistant patients. Dr. Horowitz and others have demonstrated that the HLA-E/NKG2A axis is a dominant inhibitory checkpoint pathway in solid tumors and metastasis. Afshin Dowlati, MD, is an expert in the biology and clinical management of thoracic malignancies and has led the thoracic oncology program at Case Western Reserve University since 2000. His work bridges clinical practice and translational research, with a focus on target validation and drug development, and he is uniquely positioned to advance novel therapeutics from preclinical models into the clinic. A major focus of Dr. Dowlati’s research is small cell lung cancer (SCLC), an area where progress has been limited due to an incomplete understanding of disease biology. He has established a robust research infrastructure, including a retrospective clinical-pathologic database of over 800 SCLC patients treated at his institution over more than 15 years. This resource is complemented by genomic and transcriptomic data, enabling identification of clinically relevant mutations associated with survival and treatment response. His team utilizes cell line and mouse models to investigate these genomic drivers and generate data to support future clinical trials. He is also a founding member of an SCLC consortium dedicated to advancing research and treatment in this field, and has recently initiated efforts to define molecular predictors of response to immune checkpoint inhibitors in SCLC. Alexander Shoushtari, MD, is a highly regarded medical oncologist based in New York, New York. He specializes in treating melanoma, particularly acral, mucosal, and uveal types, and is known for his expertise in cell- and immune-based therapies. Dr. Shoushtari has extensive experience in various oncology fields and is Associate Attending Physician at Memorial Sloan Kettering Cancer Center, where he has the largest practice for treating patients with melanoma. He is also an Assistant Attending Physician at the same institution, where he focuses on melanoma treatment and research. Dr. Shoushtari is a board-certified medical oncologist and has been in practice for over 15 years, offering a wealth of knowledge and experience to his patients. Max S. Topp, MD, is head of haematology and associate Professor for translational immunology at the medical clinic II at the Universitätsklinikum Würzburg, Germany. After completing his medical degree at the University of Berlin, Germany, he undertook residencies at the Free University of Berlin and the University of Tübingen, both in Germany, and a postdoctoral fellowship in immunotherapy at the Fred Hutchinson Cancer Research Center in Seattle, USA. He is board certified in internal medicine and hematology/oncology and was appointed as Associated Professor for Translational Immunology in 2011 and Head of Hematology in 2014 at the Universitätsklinikum Würzburg. Professor Topp’s research interests are in immunotherapy, both bispecific antibody constructs and CAR-T cells of leukemia and lymphomas. In addition, he has been the principal investigator in numerous trials for acute lymphoblastic leukemia, Hodgkin’s lymphoma and diffuse large B-cell lymphoma. He is also a steering committee member of the German ALL Study Group and the German Hodgkin Lymphoma Study Group.